North America Migraine Treatment Market, By Types of Migraine (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays and Others), Product Type (Prescription and Over The Counter), Type (Branded and Generic) End User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies And Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2027
Migraine treatment market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 11.8% in the forecast period of 2020 to 2027 and expected to reach USD 7,245.38 million by 2027. Rising prevalence of migraine and development of novel drugs, are the major drivers which propelled the demand of the market in the forecast period.
Migraine treatment comprises features such as technological advancement for the treatment of acute migraine will impact in launching new product by the manufactures into the market which enhance its demand as well as rising collaborations, and merger & acquisitions among the market players has enhanced the demand of migraine treatment. Currently various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative and advanced migraine treatment drugs which expected to provide various other opportunities in the migraine treatment market. However, recall of drugs and adverse effects of drugs expected to restraint the market growth in the forecast period.
The migraine treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Migraine treatment market is segmented on the basis of types of migraine, treatment, route of administration, product type, type, end user and distribution channel. The growth among segments helps you to analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of types of migraine, the market is segmented into episodic, chronic, migraine with aura and others. Episodic segment is expected to dominate the market as it is most prevalent migraine form as well as volume of treatment of episodic migraine is higher as compared to other type of migraine.
- On the basis of treatment, the market is segmented into acute/abortive treatment, preventive/prophylactic treatment, non-pharmacological therapies and devices. Acute/abortive treatment is expected to dominate the market as so many advancement has been seen in acute/abortive treatment as compared to that of the preventive/prophylactic treatment, non-pharmacological therapies and devices.
- On the basis of route of administration, the market is segmented into oral, parenteral, nasal sprays and others. Oral segment is expected to dominate the market due to availability of large number of drugs which administered by oral route and are considered as first line of therapy with high effectiveness.
- On the basis of product type, the market is segmented into prescription and over the counter. Prescription segment is expected to dominate the market as majority of migraine treatment drugs such as CGRP antagonists, calcium channel blockers, beta-blockers, and others are available only on prescription basis.
- On the basis of type, the market is segmented into branded and generic. Generic segment is expected to dominate the market due to low cost of generic drugs as well as the subsequent support by the government across different countries of the world.
- On the basis of end user, the market is segmented into hospitals, clinics, homecare and others. Hospital segment is expected to dominate the market as based on the severity of the migraine attack, patients are admitted to hospital for aggressive treatment, along with this the other factor favouring the dominance of hospital is number of hospitals which are more as compared to that of clinics and homecare.
- On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. Hospital pharmacies segment is expected to dominate the market as most of the patients who visit hospitals for the migraine treatment feel convenient to purchase drugs from the hospital pharmacy.
Migraine Treatment Market Country Level Analysis
The migraine treatment market is analysed and market size information is provided by type of migraine, treatment, route of administration, product type, type, end user and distribution channel.
The countries covered in migraine treatment market report are the U.S., Canada and Mexico in the North America.
The U.S. is dominating the North America migraine treatment market because of large number of companies operating in the market along with increasing focus of authorities on migraine as a major disability hampering the optimum economic growth of the country. Moreover, the launch of novel drugs in the country makes it an important market for branded drugs as well.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, launch of new drugs, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Availability of Large Number of Generic Drugs is propelling the Market Growth
Migraine treatment market also provides you with detailed market analysis for every country growth in migraine treatment industry with migraine treatment sales, impact of advancement in the migraine treatment and changes in regulatory scenarios with their support for the migraine treatment market. The data is available for historic period 2010 to 2018.
Competitive Landscape and Migraine Treatment Market Share Analysis
Migraine treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to migraine treatment market.
The major players covered in the report are Eli Lilly and Company, AstraZeneca, Amgen Inc., Allergan, Pfizer Inc., GlaxoSmithKline plc., Biohaven Pharmaceuticals, Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd), Bausch Health Companies Inc., Abbott, Dr. Reddy’s Laboratories Ltd., Lundbeck, Merck Sharp & Dohme Corp. (A Subsidiary of Merck& Co. Inc.), Novartis AG, Otsuka Pharmaceutical Co., Ltd (A Subsidiary of Otsuka Holdings Co., Ltd.), Catalent, Inc, Bayer AG, Sun Pharmaceutical Industries Ltd., Neurelis, Inc., Zosano Phamra Corporation, Impel NeuroPharma, Inc., among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launch, approval, partnership and agreement are also initiated by the companies’ worldwide which are also accelerating the migraine treatment market.
- In May 2018 Amgen Inc. received FDA approval for Aimovig, a product for the treatment of migraine in adults which acts by blocking the calcitonin gene-related peptide receptor (CGRP-R). This has helped the company to increase its product portfolio of migraine treatment globally.
- In December 2019 Allergan received FDA approval for UBRELVY (ubrogepant) for the acute treatment of migraine. This is the first CGRP antagonist which can be administered orally. This product approval has helped the company to enhance its revenue by increasing product sale.
Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the migraine treatment market which also provides the benefit for organisation to improve their offering for migraine treatment.
Customization Available: North America Migraine Treatment Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.